|Bid||3.1000 x 900|
|Ask||0.0000 x 1100|
|Day's Range||3.0500 - 3.2500|
|52 Week Range||0.9060 - 4.3600|
|Beta (3Y Monthly)||1.54|
|PE Ratio (TTM)||2.01|
|Earnings Date||Nov 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.48|
IVERIC bio's (ISEE) third-quarter earnings improve year over year. The company plans to initiate a pivotal study on Zimura for treating GA early next year.
IVERIC bio, Inc. (ISEE) today provided further clinical details and its development strategy for Zimura® (avacincaptad pegol), a novel complement C5 inhibitor, for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). Based on the study design and the robustness of the recently announced topline data from a randomized, double masked, sham controlled Zimura clinical trial, the Company believes that only one additional pivotal, randomized, double masked, sham controlled clinical trial would potentially be needed to demonstrate the safety and efficacy of Zimura in GA secondary to dry AMD in a manner sufficient to support regulatory approval, assuming that Zimura’s safety and efficacy profile remains consistent with the findings observed to date and subject to regulatory review.
IVERIC bio, Inc. (ISEE) today reported that on November 1, 2019, the Company granted Dr. Abraham Scaria a non-statutory stock option to purchase 300,000 shares of the Company’s common stock. In addition, on November 1, 2019, the Company granted Dr. Scaria 50,000 restricted stock units for shares of the Company’s common stock.
- Company to Host a Zimura® R&D Symposium for Investors on November 20, 2019 -
Dr. Scaria will lead the Company’s research and pre-clinical gene therapy activities. Dr. Scaria’s extensive experience includes positions at Genzyme, Sanofi and most recently at Casebia Therapeutics, leading multiple ocular gene therapy programs.
- Overall Data Suggest a Dose Response Relationship Across Treatment Groups -
If you're interested in IVERIC bio, Inc. (NASDAQ:ISEE), then you might want to consider its beta (a measure of share...
NEW YORK , Oct. 13, 2019 /PRNewswire/ -- Allegiant Travel Company (ALGT) Lifshitz & Miller announces investigation into possible securities laws in connection with a CBS News 60 Minutes segment criticizing ...
Kaskela Law LLC has commenced an investigation of IVERIC bio, Inc. , formerly known as Ophthotech Corp., on behalf of the Company’s stockholders.
In the first sentence of the release, the date and time should read: Monday, October 7, 2019 at 8:00 a.m. Eastern Time (instead of: Monday, October 7, 2019 at 8:30 a.m. Eastern Time). IVERIC bio, Inc. (ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer and President of IVERIC bio, will present an overview of the Company at the Chardan Capital Markets 3rd Annual Genetic Medicines Conference in New York on Monday, October 7, 2019 at 8:00 a.m. Eastern Time.
Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against Trevena, Inc. (TRVN) ('' Trevena ''). Last year, a class action complaint was filed against Trevena and certain of its officers and directors.
IVERIC bio (ISEE) second-quarter earnings improve year over year. The company is focusing on developing gene therapies for treating inherited retinal diseases.
IVERIC bio, Inc. (ISEE) and Catalent Biologics, today announced that they have entered into an agreement for production and manufacturing of GMP-grade adeno-associated virus (AAV) vector for IVERIC bio’s gene therapy product candidates, IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for the treatment of BEST1 related retinal diseases. IVERIC bio expects to initiate Phase 1/2 clinical trials for IC-100 in 2020 and IC-200 in the first half of 2021. IVERIC bio has engaged Paragon Gene Therapy, part of Catalent Biologics, to provide materials for preclinical activities and its planned Phase 1/2 clinical trials for both product candidates.
IVERIC bio (ISEE) first-quarter earnings beat estimates. The company is focusing on developing gene therapies for treating inherited retinal diseases.
On a per-share basis, the New York-based company said it had a loss of 30 cents. The company's shares closed at $1.44. A year ago, they were trading at $2.63. _____ This story was generated by Automated ...